A Phase 3 Study to Investigate the Efficacy and Safety of SYR-322 When Used in Combination With Insulin Preparation in Subjects With Type 2 Diabetes in Japan
A Phase 3 Study to Investigate the Efficacy and Safety of SYR-322 When Used in Combination With Insulin Preparation in Subjects With Type 2 Diabetes in Japan
To determine the efficacy and safety of SYR-322 (alogliptin) 25-mg, once daily (QD), in patients with diabetes when used in combination with insulin.
Inclusion Criteria:
Exclusion Criteria:
Hirosaki-shi, Aomori, Japan
Kashiwa-shi, Chiba, Japan
Kisarazu-shi, Chiba, Japan
Kitakyushu-shi, Fukuoka, Japan
Aki-gun, Hiroshima, Japan
Fukuyama-shi, Hiroshima, Japan
Nishinomiya-shi, Hyōgo, Japan
Koga-shi, Ibaraki, Japan
Ushiku-shi, Ibaraki, Japan
Kahoku-gun, Ishikawa-ken, Japan
Hanamaki-shi, Iwate, Japan
Satsuma-sendai-shi, Kagoshima-ken, Japan
Minamata-shi, Kumamoto, Japan
Nigata-shi, Niigata, Japan
Hirakata-shi, Osaka, Japan
Osaka-sayama-shi, Osaka, Japan
Takatsuki-shi, Osaka, Japan
Yao-shi, Osaka, Japan
Kuki-shi, Saitama, Japan
Shimotsuke-shi, Tochigi, Japan
Shinagawa-ku, Tokyo, Japan
Sagae-shi, Yamagata, Japan